All News
Mucosal Disruptions as Initiators of Rheumatoid Arthritis
Many have suggested that microbiome and mucosal disruptions are contributors to autoimmunity, especially rheumatoid arthritis (RA). This is partly represented in what is known as the "mucosal hypothesis" to RA. A current review article by Hollers, et al. addresses how distinct mucosal endotypes can serve as drivers or initiators of RA.
Read Article
Analgesic Prescribing in Patients with Inflammatory Arthritis
A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis (IA) patients has declined, but still remains substantial, including opioid prescribing.
Stop Counting Bugs (10.4.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.
Read Article
2023 EULAR Recommendations on Management of Fatigue
A 2023 EULAR task force has made recommendations to the approach and management of fatigue in patients with inflammatory rheumatic and musculoskeletal diseases (I-RMDs).
ASAS Imaging Recommendations for Suspected Spondyloarthritis
ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA).
Read Article
Which One is the Loneliest Number (9.27.2024)
Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.
Read Article
Stratified Cancer Screening in Dermatomyositis
The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.
Read Article
INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis
The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.
Read Article
Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.
Read Article
Mycophenolate in New-Onset SLE
How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?
Read Article
TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients
Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.
Read Article
FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis
A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).